Repligen Corp. (NASDAQ:RGEN) of Cambridge, Mass., announcedthat the compound AM285, developed by the company'ssubsidiary, Amira Inc., has demonstrated the ability to inhibitsolid tumor growth in animals.
The results of the study, published in the July issue of CancerResearch by Amira co-founder Dr. Rima Kaddurah-Daouk andher research team, showed that AM285 significantly inhibitedthe size of established cervical carcinoma tumors in mice. Italso inhibited the ability of small cell lung, colon, ovarian,kidney and cervical cancer cells to form colonies in vitro. Thegrowth of normal cells was not inhibited, however.
AM285 is a small molecule that Amira has developed tomodulate cellular energy processes that have been implicatedin cancer. It modulates energy flow through the enzymecreatine kinase.
(c) 1997 American Health Consultants. All rights reserved.